Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: ...

Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...